ImmunoGen announces $200M common stock offering
The Fly

ImmunoGen announces $200M common stock offering

ImmunoGen announced that it intends to offer and sell, subject to market and other conditions, $200M of shares of its common stock in an underwritten public offering. ImmunoGen intends to use the net proceeds from this offering to fund its operations, including, but not limited to, global commercialization activities, supply of ELAHERE drug product, clinical trial activities, pipeline research and development activities, business development activities, and capital expenditures. Jefferies, Goldman Sachs & Co., and Guggenheim Securities are acting as joint book-running managers for the proposed offering.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on IMGN:

Related Articles
TheFlyTwo option delistings on February 21st
TipRanks Auto-Generated NewsdeskImmunoGen Finalizes Merger, Amends Operations, and Delists Shares
TheFlyAbbVie completes the acquisition of ImmunoGen
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App